Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report
10.3393/ac.2020.00213.0030
- Author:
Hye Jung CHO
1
;
Woo Ram KIM
;
Joo-Hang KIM
;
Duk Hwan KIM
;
Dae Jung KIM
;
Haeyoun KANG
Author Information
1. Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- Publication Type:Case Report
- From:Annals of Coloproctology
2021;37(Suppl 1):S39-S43
- CountryRepublic of Korea
- Language:English
-
Abstract:
With the advent of checkpoint inhibitors, it has opened up opportunities for numerous cancer patients. However, as is the case with every treatment, complications need to be weighed. Gastrointestinal adverse effects, such as diarrhea and colitis are well-known complications for checkpoint inhibitors. In severe cases, colitis-induced colonic perforation may occur with an estimation of 1.0% to 1.5% in anti-CTLA-4 antibodies. However, only a handful of cases of such devastating complications have been reported in anti-PD-1 antibodies such as pembrolizumab and nivolumab. We here report a case of intestinal perforation in a patient treated with nivolumab.
